Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 14/20 | 0.57 |
| ▸ | ACACB | O00763 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.40 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.40 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.40 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6683466 | 0.90 | CNR1 (0.46) | CNR1ACACB | |
| SCHEMBL6677304 | 0.89 | CNR1 (0.54) | CNR1ACACBCNR2 | |
| SCHEMBL6800924 | 0.87 | CNR1 (0.58) | CNR1ACACBCNR2ABCC9ABCC8 | |
| SCHEMBL6681129 | 0.86 | CNR1 (0.42) | CNR1ACACBABCC9ABCC8KCNJ11 | |
| SCHEMBL6805179 | 0.85 | CNR1 (0.56) | CNR1ACACBCNR2ABCC9ABCC8 | |
| SCHEMBL6541208 | 0.85 | CNR1 (0.56) | CNR1ACACBCA2 | |
| SCHEMBL6679390 | 0.85 | METAP2 (0.42) | CNR1ACACBABCC9ABCC8KCNJ11 | |
| SCHEMBL6693250 | 0.84 | CNR1 (0.41) | CNR1ACACBABCC9ABCC8KCNJ11 | |
| SCHEMBL6687524 | 0.83 | CNR1 (0.40) | CNR1ACACBABCC9ABCC8KCNJ11 | |
| SCHEMBL6540898 | 0.82 | ABCC9 (0.57) | CNR1ACACBABCC9ABCC8KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | CNR1 112/4885ACACB 1800/4885CNR2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.